Bayer AG (BAYRY) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, Bayer AG (BAYRY) es una empresa del sector Healthcare valorada en 0. La acción obtiene una puntuación de 51/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 15 mar 2026Bayer AG (BAYRY) Resumen de Asistencia Médica y Tuberías
Bayer AG, a life science company established in 1863, operates across pharmaceuticals, consumer health, and crop science, providing prescription drugs, over-the-counter medicines, and agricultural solutions. With a global presence and a focus on innovation, Bayer faces competition from both established pharmaceutical companies and agricultural technology firms.
Tesis de Inversión
Bayer AG presents a complex investment case. With a market capitalization of $43.19 billion, the company's negative P/E ratio of -10.49 and a negative profit margin of -7.9% reflect current challenges. The dividend yield of 0.28% offers modest income. Growth catalysts include potential breakthroughs in oncology and strategic partnerships. However, the company faces risks related to regulatory hurdles, patent expirations, and potential liabilities from its Crop Science segment. Investors should carefully weigh these factors when evaluating Bayer's long-term potential.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market Cap of $43.19B reflects Bayer's substantial size within the life science industry.
- Gross Margin of 58.8% indicates strong pricing power in its key product segments.
- Negative P/E Ratio of -10.49 suggests current earnings challenges.
- Dividend Yield of 0.28% provides a modest return for investors.
- Beta of 0.93 indicates lower volatility compared to the overall market.
Competidores y Pares
Fortalezas
- Diversified business segments across pharmaceuticals, consumer health, and crop science.
- Strong brand reputation and global presence.
- Extensive research and development capabilities.
- Established distribution network and customer relationships.
Debilidades
- Negative profit margin and P/E ratio.
- Potential liabilities related to Crop Science segment.
- Exposure to regulatory risks and patent expirations.
- Dependence on successful product development and commercialization.
Catalizadores
- Upcoming: Potential regulatory approvals for new pharmaceutical products in key markets.
- Ongoing: Strategic collaborations with MD Anderson Cancer Center and other research institutions.
- Ongoing: Expansion of digital solutions for agriculture to improve crop yields.
- Upcoming: Launch of new consumer health products targeting specific health needs.
- Ongoing: Cost-cutting initiatives to improve profitability and efficiency.
Riesgos
- Ongoing: Potential liabilities related to the Crop Science segment and glyphosate-related lawsuits.
- Potential: Regulatory hurdles and delays in obtaining approvals for new products.
- Ongoing: Patent expirations and generic competition for key pharmaceutical products.
- Potential: Economic downturns and market volatility affecting demand for products.
- Potential: Currency fluctuations impacting revenue and profitability.
Oportunidades de crecimiento
- Expansion in Oncology: Bayer has ongoing collaborations with MD Anderson Cancer Center to develop oncology drugs. The global oncology market is projected to reach $350 billion by 2030, presenting a significant growth opportunity for Bayer. Successful development and commercialization of new cancer therapies could drive substantial revenue growth.
- Strategic Partnerships in Pharmaceuticals: Bayer's research and license agreement with Dewpoint Therapeutics focuses on developing treatments for cardiovascular and gynecological diseases. The cardiovascular disease market is expected to reach $250 billion by 2028. Successful development of new therapies in this area could significantly boost Bayer's pharmaceutical revenues.
- Digital Solutions in Agriculture: Bayer is investing in digital solutions for agriculture to improve crop yields and sustainability. The digital agriculture market is projected to reach $12 billion by 2027. Bayer's digital platforms can provide farmers with data-driven insights, optimizing resource utilization and increasing productivity.
- Growth in Consumer Health: The consumer health market is expanding due to increasing self-care trends and an aging population. Bayer's focus on over-the-counter medicines, medical products, and nutritional supplements positions it well to capitalize on this growth. The global consumer health market is expected to reach $350 billion by 2025.
- Innovation in Crop Protection: Bayer continues to innovate in crop protection products, including chemical and biological solutions. The global crop protection market is projected to reach $80 billion by 2027. Bayer's focus on sustainable agriculture and integrated pest management can drive growth in this segment.
Oportunidades
- Expansion in oncology and other high-growth therapeutic areas.
- Strategic partnerships and collaborations to drive innovation.
- Growth in digital agriculture and sustainable farming practices.
- Increasing demand for consumer health products and self-care solutions.
Amenazas
- Intense competition from other life science companies.
- Evolving regulations and increasing scrutiny regarding product safety.
- Economic downturns and market volatility.
- Patent expirations and generic competition.
Ventajas competitivas
- Strong brand recognition and reputation in the life science industry.
- Extensive patent portfolio protecting key products and technologies.
- Global distribution network and established relationships with customers.
- Significant investment in research and development, driving innovation.
Acerca de BAYRY
Founded in 1863 in Leverkusen, Germany, Bayer Aktiengesellschaft has evolved from a dyestuff factory into a global life science powerhouse. The company operates through three primary segments: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals segment develops and markets prescription products, focusing on cardiology, women's health, oncology, hematology, and ophthalmology, along with diagnostic imaging equipment and cell and gene therapy. The Consumer Health segment offers a wide range of nonprescription medicines, medical products, and self-care solutions in areas like dermatology, nutritional supplements, pain relief, digestive health, and allergy. The Crop Science segment provides chemical and biological crop protection products, seeds, and digital solutions for agriculture, supporting farmers in improving yields and sustainability. Bayer distributes its products through various channels, including wholesalers, pharmacies, supermarkets, online retailers, and directly to farmers. Through strategic collaborations with institutions like MD Anderson Cancer Center and the University of Oxford, Bayer continues to innovate and expand its product portfolio.
Qué hacen
- Develop and market prescription drugs for various therapeutic areas.
- Offer over-the-counter medicines and self-care solutions.
- Provide crop protection products, seeds, and digital solutions for agriculture.
- Develop diagnostic imaging equipment and contrast agents.
- Engage in cell and gene therapy research and development.
- Offer products for cardiology and women's health care.
- Provide solutions for oncology, hematology, and ophthalmology.
Modelo de Negocio
- Develop, manufacture, and market pharmaceutical products.
- Produce and distribute consumer health products through various channels.
- Offer crop science solutions to farmers and agricultural businesses.
- Generate revenue through product sales, licensing agreements, and collaborations.
Contexto de la Industria
Bayer operates in the highly competitive life science industry, encompassing pharmaceuticals, consumer health, and crop science. The pharmaceutical sector is characterized by intense research and development, stringent regulatory requirements, and patent protection. The consumer health market is driven by increasing self-care trends and an aging population. The crop science industry faces challenges related to sustainability, climate change, and food security. Bayer competes with major players like ALPMF, ALPMY, FSNUF, GIKLY, and JDHIF, all vying for market share through innovation and strategic partnerships. The industry is subject to evolving regulations and increasing scrutiny regarding environmental impact and product safety.
Clientes Clave
- Patients who use prescription and over-the-counter medications.
- Consumers who purchase self-care products and nutritional supplements.
- Farmers and agricultural businesses who use crop protection products and seeds.
- Hospitals and healthcare providers who use diagnostic imaging equipment.
Finanzas
Gráfico e información
Precio de la acción de Bayer AG (BAYRY): Price data unavailable
Últimas noticias
-
Multiplatinum Rapper, Actor Ludacris Partners with One A Day® to Help People Realize that Health Does Not Need to Be Ludacris
Yahoo! Finance: BAYRY News · 26 mar 2026
-
Bayer: Turnaround Is Underway - Don't Miss It
seekingalpha.com · 26 mar 2026
-
Bayer Crop Science Canada Redefines Canola Innovation With New "Advancing Better Canola" Initiative
businesswire.com · 26 mar 2026
-
Short Interest in Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Grows By 178.9%
defenseworld.net · 25 mar 2026
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para BAYRY.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para BAYRY.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de BAYRY en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Últimas Noticias
Multiplatinum Rapper, Actor Ludacris Partners with One A Day® to Help People Realize that Health Does Not Need to Be Ludacris
Bayer: Turnaround Is Underway - Don't Miss It
Bayer Crop Science Canada Redefines Canola Innovation With New "Advancing Better Canola" Initiative
Short Interest in Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Grows By 178.9%
Liderazgo: William N. Anderson
Unknown
Information on William N. Anderson's background is not available in the provided data. Without additional context, it is impossible to provide details on his career history, education, or previous roles.
Historial: Information on William N. Anderson's track record is not available in the provided data. Without additional context, it is impossible to provide details on his key achievements, strategic decisions, or company milestones under his leadership.
Información de ADR de Bayer AG No patrocinado
An American Depositary Receipt (ADR) like BAYRY represents shares of a foreign company (Bayer AG) held by a U.S. depositary bank. This allows U.S. investors to trade shares of Bayer AG on U.S. exchanges as if they were domestic securities, simplifying the process of investing in foreign companies.
- Ticker del mercado local: Frankfurt Stock Exchange (BAYR), Germany
- Nivel de ADR: 1
- Ratio de ADR: 1:1
- Ticker del mercado local: BAYR
Información del mercado OTC de BAYRY
The OTC Other tier is the lowest tier of the over-the-counter (OTC) market, indicating that Bayer AG (BAYRY) has chosen not to meet the requirements for higher tiers like OTCQX or OTCQB. Companies on the OTC Other tier may have limited financial disclosure and do not have to adhere to the same listing standards as companies on the NYSE or NASDAQ. This tier is often associated with higher risk and less liquidity compared to listed exchanges.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure and transparency.
- Lower trading volume and liquidity.
- Potential for wider bid-ask spreads and price volatility.
- Higher risk of fraud or manipulation compared to listed exchanges.
- Less regulatory oversight and investor protection.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Check for any legal or regulatory issues.
- Monitor trading volume and price activity.
- Consult with a financial advisor before investing.
- Bayer AG is a well-established company with a long history.
- The company operates in regulated industries (pharmaceuticals, consumer health, crop science).
- Bayer AG has a global presence and a diverse product portfolio.
- The company is subject to regulatory oversight in its primary markets (e.g., Germany).
- Bayer AG has strategic partnerships with reputable institutions.
Lo Que los Inversores Preguntan Sobre Bayer AG (BAYRY)
¿Cuáles son los factores clave para evaluar BAYRY?
Bayer AG (BAYRY) actualmente tiene una puntuación IA de 51/100, indicando puntuación moderada. Fortaleza clave: Diversified business segments across pharmaceuticals, consumer health, and crop science.. Riesgo principal a monitorear: Ongoing: Potential liabilities related to the Crop Science segment and glyphosate-related lawsuits.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de BAYRY?
BAYRY actualmente puntúa 51/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de BAYRY?
Los precios de BAYRY se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre BAYRY?
La cobertura de analistas para BAYRY incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en BAYRY?
Las categorías de riesgo para BAYRY incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: Potential liabilities related to the Crop Science segment and glyphosate-related lawsuits.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de BAYRY?
La relación P/E para BAYRY compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está BAYRY sobrevalorada o infravalorada?
Determinar si Bayer AG (BAYRY) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de BAYRY?
Bayer AG (BAYRY) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide additional insights.